Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) Enterprise Value (2016 - 2026)

CorMedix has reported Enterprise Value over the past 16 years, most recently at -$155.2 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$155.2 million for Q4 2025, down 200.27% from a year ago — trailing twelve months through Dec 2025 was -$155.2 million (down 200.27% YoY), and the annual figure for FY2025 was -$155.2 million, down 200.27%.
  • Enterprise Value reached -$155.2 million in Q4 2025 per CRMD's latest filing, down from -$55.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$19.8 million in Q2 2023 and bottomed at -$190.7 million in Q2 2025.
  • Median Enterprise Value over the past 5 years was -$55.7 million (2023), compared with a mean of -$66.3 million.
  • The largest annual shift saw Enterprise Value plummeted 342.79% in 2021 before it skyrocketed 68.91% in 2022.
  • Over 5 years, Enterprise Value stood at -$53.4 million in 2021, then rose by 19.04% to -$43.3 million in 2022, then decreased by 1.03% to -$43.7 million in 2023, then dropped by 18.22% to -$51.7 million in 2024, then plummeted by 200.27% to -$155.2 million in 2025.
  • Business Quant data shows Enterprise Value for CRMD at -$155.2 million in Q4 2025, -$55.7 million in Q3 2025, and -$190.7 million in Q2 2025.